Asset profile

Linvoseltamab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved — Multiple Myeloma

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (1)
August 2027 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-08-31 · NCT06376526 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (3)
February 2028 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2028-02-01 · NCT07009899 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-06-30 · NCT07181941 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)
Phase 1/2Relapsed/Refractory Systemic Light Chain AmyloidosisRecruiting
Est. primary completion 2028-08-20 · NCT06292780 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
May 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (2)
May 2032 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-05-18 · NCT06140524 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2032 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-12-02 · NCT06910124 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (7)
January 2033 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2033-01-25 · NCT05955508 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2033 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2033-03-30 · NCT03761108 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2033 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-04-19 · NCT05730036 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2033 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-07-27 · NCT07393282 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2033 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2033-09-30 · NCT07455851 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2033 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2033-10-01 · NCT07624513 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2033 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2033-11-11 · NCT06669247 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2035 (1)
November 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-11-02 · NCT05828511 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2036 (1)
December 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-12 · NCT06932562 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.